Literature DB >> 28587876

Strength of cholinergic tone dictates the polarity of dopamine D2 receptor modulation of striatal cholinergic interneuron excitability in DYT1 dystonia.

Mariangela Scarduzio1, Chelsea N Zimmerman1, Karen L Jaunarajs1, Qin Wang2, David G Standaert1, Lori L McMahon3.   

Abstract

Balance between cholinergic and dopaminergic signaling is central to striatal control of movement and cognition. In dystonia, a common disorder of movement, anticholinergic therapy is often beneficial. This observation suggests there is a pathological increase in cholinergic tone, yet direct confirmation is lacking. In DYT1, an early-onset genetic form of dystonia caused by a mutation in the protein torsinA (TorA), the suspected heightened cholinergic tone is commonly attributed to faulty dopamine D2 receptor (D2R) signaling where D2R agonists cause excitation of striatal cholinergic interneurons (ChIs), rather than the normal inhibition of firing observed in wild-type animals, an effect known as "paradoxical excitation". Here, we provide for the first time direct measurement of elevated striatal extracellular acetylcholine (ACh) in a knock-in mouse model of human DYT1 dystonia (TorA∆E/+ mice), confirming a striatal hypercholinergic state. We hypothesized that this elevated extracellular ACh might cause chronic over-activation of muscarinic acetylcholine receptors (mAChRs) and disrupt normal D2R function due to their shared coupling to Gi/o-proteins. We tested this concept in vitro first using a broad-spectrum mAChR antagonist, and then using a M2/M4 mAChR selective antagonist to specifically target mAChRs expressed by ChIs. Remarkably, we found that mAChR inhibition reverses the D2R-mediated paradoxical excitation of ChIs recorded in slices from TorA∆E/+ mice to a typical inhibitory response. Furthermore, we recapitulated the paradoxical D2R excitation of ChIs in striatal slices from wild-type mice within minutes by simply increasing cholinergic tone through pharmacological inhibition of acetylcholinesterase (AChE) or by prolonged agonist activation of mAChRs. Collectively, these results show that enhanced mAChR tone itself is sufficient to rapidly reverse the polarity of D2R regulation of ChI excitability, correcting the previous notion that the D2R mediated paradoxical ChI excitation causes the hypercholinergic state in dystonia. Further, using a combination of genetic and pharmacological approaches, we found evidence that this switch in D2R polarity results from a change in coupling from the preferred Gi/o pathway to non-canonical β-arrestin signaling. These results highlight the need to fully understand how the mutation in TorA leads to pathologically heightened extracellular ACh. Furthermore the discovery of this novel ACh-dopamine interaction and the participation of β-arrestin in regulation of cholinergic interneurons is likely important for other basal ganglia disorders characterized by perturbation of ACh-dopamine balance, including Parkinson and Huntington diseases, l-DOPA-induced dyskinesia and schizophrenia.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cholinergic interneurons; D2 receptors; DYT1; Dopamine-acetylcholine interaction; Dorsal striatum; Dystonia; GPCRs; Muscarinic receptors; β-arrestin

Mesh:

Substances:

Year:  2017        PMID: 28587876      PMCID: PMC5561742          DOI: 10.1016/j.expneurol.2017.06.005

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  56 in total

Review 1.  The Akt-GSK-3 signaling cascade in the actions of dopamine.

Authors:  Jean-Martin Beaulieu; Raul R Gainetdinov; Marc G Caron
Journal:  Trends Pharmacol Sci       Date:  2007-03-08       Impact factor: 14.819

2.  Muscarinic receptor activation attenuates D2 dopamine receptor mediated inhibition of acetylcholine release in rat striatum: indications for a common signal transduction pathway.

Authors:  B Drukarch; E Schepens; J C Stoof
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

3.  Muscarinic (m2/m4) receptors reduce N- and P-type Ca2+ currents in rat neostriatal cholinergic interneurons through a fast, membrane-delimited, G-protein pathway.

Authors:  Z Yan; D J Surmeier
Journal:  J Neurosci       Date:  1996-04-15       Impact factor: 6.167

Review 4.  Acetylcholine-dopamine balance hypothesis in the striatum: an update.

Authors:  Toshihiko Aosaki; Masami Miura; Takeo Suzuki; Kinya Nishimura; Masao Masuda
Journal:  Geriatr Gerontol Int       Date:  2010-07       Impact factor: 2.730

5.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

6.  Synaptic vesicle recycling is enhanced by torsinA that harbors the DYT1 dystonia mutation.

Authors:  Yasuhiro Kakazu; Jin-Young Koh; K W David Ho; Pedro Gonzalez-Alegre; N Charles Harata
Journal:  Synapse       Date:  2012-02-15       Impact factor: 2.562

7.  Effect of torsinA on membrane proteins reveals a loss of function and a dominant-negative phenotype of the dystonia-associated DeltaE-torsinA mutant.

Authors:  Gonzalo E Torres; Ava L Sweeney; Jean-Martin Beaulieu; Pullani Shashidharan; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-25       Impact factor: 11.205

Review 8.  The pathophysiological basis of dystonias.

Authors:  Xandra O Breakefield; Anne J Blood; Yuqing Li; Mark Hallett; Phyllis I Hanson; David G Standaert
Journal:  Nat Rev Neurosci       Date:  2008-03       Impact factor: 34.870

9.  Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action.

Authors:  Nikhil M Urs; Joshua C Snyder; Jacob P R Jacobsen; Sean M Peterson; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-27       Impact factor: 11.205

10.  Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons.

Authors:  Sarah Threlfell; Tatjana Lalic; Nicola J Platt; Katie A Jennings; Karl Deisseroth; Stephanie J Cragg
Journal:  Neuron       Date:  2012-07-12       Impact factor: 17.173

View more
  30 in total

Review 1.  Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Authors:  Maryka Quik; James T Boyd; Tanuja Bordia; Xiomara Perez
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

2.  Complex Control of Striatal Neurotransmission by Nicotinic Acetylcholine Receptors via Excitatory Inputs onto Medium Spiny Neurons.

Authors:  Valentina Licheri; Oona Lagström; Amir Lotfi; Mary H Patton; Holger Wigström; Brian Mathur; Louise Adermark
Journal:  J Neurosci       Date:  2018-06-25       Impact factor: 6.167

3.  Diverse Mechanisms Lead to Common Dysfunction of Striatal Cholinergic Interneurons in Distinct Genetic Mouse Models of Dystonia.

Authors:  Karen L Eskow Jaunarajs; Mariangela Scarduzio; Michelle E Ehrlich; Lori L McMahon; David G Standaert
Journal:  J Neurosci       Date:  2019-07-18       Impact factor: 6.167

Review 4.  The neurobiological basis for novel experimental therapeutics in dystonia.

Authors:  Anthony M Downs; Kaitlyn M Roman; Simone A Campbell; Antonio Pisani; Ellen J Hess; Paola Bonsi
Journal:  Neurobiol Dis       Date:  2019-07-04       Impact factor: 5.996

5.  The HIV protease inhibitor, ritonavir, corrects diverse brain phenotypes across development in mouse model of DYT-TOR1A dystonia.

Authors:  Zachary F Caffall; Bradley J Wilkes; Ricardo Hernández-Martinez; Joseph E Rittiner; Jennifer T Fox; Kanny K Wan; Miranda K Shipman; Steven A Titus; Ya-Qin Zhang; Samarjit Patnaik; Matthew D Hall; Matthew B Boxer; Min Shen; Zhuyin Li; David E Vaillancourt; Nicole Calakos
Journal:  Sci Transl Med       Date:  2021-08-18       Impact factor: 17.956

6.  Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia.

Authors:  Anthony M Downs; Xueliang Fan; Christine Donsante; H A Jinnah; Ellen J Hess
Journal:  Neurobiol Dis       Date:  2019-01-30       Impact factor: 5.996

7.  Cell-intrinsic effects of TorsinA(ΔE) disrupt dopamine release in a mouse model of TOR1A dystonia.

Authors:  Anthony M Downs; Xueliang Fan; Radhika F Kadakia; Yuping Donsante; H A Jinnah; Ellen J Hess
Journal:  Neurobiol Dis       Date:  2021-04-21       Impact factor: 5.996

Review 8.  Novel Pharmacotherapies in Parkinson's Disease.

Authors:  Yousef Tizabi; Bruk Getachew; Michael Aschner
Journal:  Neurotox Res       Date:  2021-05-18       Impact factor: 3.911

9.  Cell-specific effects of Dyt1 knock-out on sensory processing, network-level connectivity, and motor deficits.

Authors:  B J Wilkes; J C DeSimone; Y Liu; W T Chu; S A Coombes; Y Li; D E Vaillancourt
Journal:  Exp Neurol       Date:  2021-06-10       Impact factor: 5.330

10.  Investigating the role of striatal dopamine receptor 2 in motor coordination and balance: Insights into the pathogenesis of DYT1 dystonia.

Authors:  Yuning Liu; Hong Xing; Fumiaki Yokoi; David E Vaillancourt; Yuqing Li
Journal:  Behav Brain Res       Date:  2021-01-18       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.